InvestorsHub Logo
Followers 40
Posts 3318
Boards Moderated 0
Alias Born 08/18/2009

Re: None

Wednesday, 10/03/2012 7:41:32 AM

Wednesday, October 03, 2012 7:41:32 AM

Post# of 43
Misc analyst quotes about Addex on The Life Sciences Report website

http://www.thelifesciencesreport.com/pub/co/4060

(coopied without permission below, underlining added by me)

This stock is a screaming buy IMO.. hold for a few years and it's a potential 10-bagger from here.


Expert Analysis

Christopher Marai, Wedbush (9/10/12) "We view Addex Therapeutics' dipraglurant as likely to change the treatment paradigm for Parkinson's disease by prolonging and augmenting the benefits of levodopa, the current gold standard of care for the disease. . .we anticipate Phase 2 data for ADX71149 in schizophrenia from the company's partner Janssen Pharmaceuticals Inc. in early Q4/12. . .we are initiating coverage with an Outperform rating."

The Life Sciences Report Interview with Greg Wade (8/30/12) "We had a chance to catch up with our friends from Addex Therapeutics at the conference. I don't think the company has a strong U.S. following, despite what we believe are very compelling data for its metabotropic glutamate receptor 5 (mGluR5) inhibitor, dipraglurant. The company is confident that it will find a partner to develop the product, first in an indication for Parkinson's disease levodopa-induced dyskinesia (PD-LID). With support and validation, investors will come to appreciate the opportunities for the drug in the PD-LID indication. Addex is an interesting, undiscovered company, and is undervalued perhaps because of the stock's low trading volume, Swiss stock exchange listing, and the relatively modest number of patients treated in its dipraglurant clinical studies. . .with a partnership, I think Addex will be a different story. . . The trick has been specificity. I think some folks at Addex are getting to the heart of that issue as well."

Juan Sanchez, Ladenburg Thalmann (8/29/12) "We believe the schizophrenia glutamate hypothesis (the target pathway for Addex Therapeutics' ADX71149 and pomaglumetad methionilIn) is one of the strongest and most widely accepted by the scientific community. . .we look forward to top-line phase 2 results on ADX71149 in Q4/12. We are encouraged by the trial design, which evaluates (part B of the study) ADX71149 as an add-on to the currently prescribed antipsychotic. . .we reiterate our Buy rating."

Juan Sanchez, Ladenburg Thalmann (8/22/12) "In our view, Addex Therapeutics' value proposition is supported by: 1) dipraglurant for levodopa induced dyskinesia, which we believe represents a partially derisked asset in midstage of clinical development, 2) ADX71149 in Phase 2 clinical development for schizophrenia and major depressive disorder with anxiety symptoms and 3) the company's pipeline and discovery platform. . .we reiterate our Buy rating."

Juan Sanchez, Ladenburg Thalmann (6/21/12) "At the Movement Disorders Society conference in Dublin, Ireland, Addex Therapeutics presented a late breaking poster with detailed results from the dipraglurant Phase 2a trial in Parkinson's disease patients suffering from levodopa induced dyskinesia (LID). . .they confirm our assessment that the totality of the data supports the safety of dipraglurant and strongly suggests dipraglurant is an active compound (in treating LID). . .we believe the likelihood the company finds a corporate partner to continue development of dipraglurant are considerably high. . .we reiterate our Buy rating."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.